PharmaMar presents a new Antibody Drug Conjugate at the World ADC Congress in San Diego

- MI180021 ADC is the result of conjugating trastuzumab with the marine molecule PM160057.
- PM160057 is part of a new family of molecules specifically designed as new "payloads" for ADCs for treating cancer.
- This is the second new class of marine payloads for ADCs filed for patenting by PharmaMar.

Madrid, 12th of November, 2018 – PharmaMar (MSE:PHM) presents a new Antibody Drug Conjugate (ADC) MI180021, the result of linking trastuzumab with the marine molecule PM160057. This will be presented at the World ADC Congress in San Diego, from 12-15 November 2018.

PharmaMar's poster has been selected as one of the top five for an oral presentation at the Congress.

This ADC has shown potent and highly selective activity in tumor cells that overexpress HER2, as found in certain breast, gastric and pancreas cancers, among others.

PM160057 belongs to a new family of molecules of marine origin that kill tumor cells by binding to DNA. This family of new chemical structures with novel mechanisms of action offer the opportunity to develop a new generation of ADCs (also called "magic bullets").

This discovery reinforces the strategy of PharmaMar’s unit dedicated to obtaining compounds for the use of active agents in ADCs.

This research has already led to the licensing of the first family of active molecules to Seattle Genetics, world leader in ADCs, for which PharmaMar received an initial payment of $5 million.

According to Carmen Cuevas, Director of R&D at PharmaMar, "MI180021 has a high selectivity against cancer cells that overexpress HER2 receptor, providing a new opportunity to treat patients with these types of cancers, such as breast, gastric and pancreatic."

About ADCs
ADCs are innovative, next-generation immunotherapeutic agents. ADCs consist of an antibody that identifies and targets antigens on the surface of certain tumor cells, a molecule with anti-tumor activity, and a connector that binds them together. Despite more than 30 years of research to develop ADCs, there are currently only four FDA-approved conjugate antibodies (Kadcyla, Adcetris, Besponsa, and Mylotarg), two of which incorporate microtubule inhibitors (auristatins and maytansins) as active charge; and the other two, using a compound that interacts with DNA (calicheamicin).

Agents that interact with DNA are widely used in cancer treatment.

Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar
Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at www.pharmamar.com.

Media Contact:
Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000

Investor Relations:
Phone: +34 914444500

Or please visit our website at www.pharmamar.com